Shanghai Regor Enters $1.5 Billion Deal with Lilly for Metabolic Therapies

Regor Therapeutics of Shanghai entered into a $1.55 billion research pact with Eli Lilly to discover and develop novel therapies for metabolic disorders. Regor's proprietary CARD (Computer Accelerated Rational Discovery) Platform discoveries innovative candidates for oncology, immunology and metabolic disorders. Lilly will make an upfront $50 million payment for ex-China rights to several Regor metabolic therapies with an option to extend the license. Regor, which will own rights to the candidates in Greater China, is also eligible for $1.5 billion in milestones and royalties. More details.... Stock Symbol: (NYSE: LLY) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.